Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2B | O60939 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19685739 | 0.92 | CAPN1 (0.39) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19685825 | 0.89 | KDM4E (0.44) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19686031 | 0.86 | NR4A2 (0.46) | TNKS2NR4A2 | |
| SCHEMBL19686345 | 0.84 | ESRRA (0.43) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19686043 | 0.84 | ESR1 (0.40) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19685827 | 0.82 | SCN2B (0.37) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19685737 | 0.81 | KDM4E (0.41) | SCN2BSCN1ASCN1BSCN5ASCN9A | |
| SCHEMBL19685966 | 0.81 | NR4A2 (0.43) | TNKS2NR4A2 | |
| SCHEMBL11998159 | 0.78 | L3MBTL1 (0.50) | NR4A2 | |
| SCHEMBL11998158 | 0.78 | L3MBTL1 (0.50) | NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | CYC1, CCNA1, CYCS | SCN2B 3140/4885SCN1A 1889/4885SCN1B 1563/4885 |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | CYC1, CCNA1, CYCS | SCN2B 3140/4885SCN1A 1889/4885SCN1B 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.